Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679951 · ClinicalTrials.gov registry record · Phase 2
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT01679951 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 272 participants.
The verdict
NCT01679951, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
The purpose of this dose range finding study is to assess the effectiveness, safety and tolerability of JNJ-38518168 at doses of 3, 10, and 30 mg/d compared with placebo in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG JNJ-38518168 (30 mg)
- DRUG JNJ-38518168 (10 mg)
- DRUG JNJ-38518168 (3 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2014-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01679951
The ClinicalTrials.gov registry entry for NCT01679951 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01679951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01679951 about?
NCT01679951 is a clinical study titled "A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate". The purpose of this dose range finding study is to assess the effectiveness, safety and tolerability of JNJ-38518168 at doses of 3, 10, and 30 mg/d compared with placebo in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy.
What is the current status of trial NCT01679951?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2012-10-31. Estimated completion is 2014-07-03.
What interventions are being tested in trial NCT01679951?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), JNJ-38518168 (30 mg) (DRUG), JNJ-38518168 (10 mg) (DRUG), JNJ-38518168 (3 mg) (DRUG).
Who is sponsoring clinical trial NCT01679951?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.